Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Novel Drug Studies Yield Biomarker Candidates for Prostate Cancer Bone Turnover

September 4th 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

Ginseng Improves Cancer-Related Fatigue in Phase III Trial

September 3rd 2013

A multisite, randomized, double-blind trial evaluating the fatigue-ameliorating properties of American ginseng in cancer patients and recent survivors has found the herb to be helpful in reducing some aspects of CRF, with the benefit strongest among patients currently in treatment.

New Life for PARP Inhibitors: Emerging Agents Leave Mark at ASCO

August 30th 2013

Anticancer agents that inhibit the poly (ADP-ribose) polymerase (PARP) family of enzymes have defined a new therapeutic paradigm known as synthetic lethality.

Did Our Founding Fathers Get It Right?

August 28th 2013

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

Dr. Matthew J. Ellis on the Future of TCGA

August 27th 2013

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Dr. Gaspar on Reducing Neurotoxicity in Lung Cancer

August 26th 2013

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Developments in Metastatic Cancer

August 23rd 2013

Over the past several years, several new approaches to treatment have prolonged and improved quality of life for patients with metastases.

Conclusion: Final Thoughts on Treatment Advances in NSCLC

August 21st 2013

Selecting a First-Line EGFR Inhibitor in NSCLC

August 21st 2013

GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

August 21st 2013

Novel Immunotherapy Combinations in NSCLC

August 21st 2013

Targeting the Immune System in Non-Small Cell Lung Cancer

August 21st 2013

Case Study: Treating KRAS-Mutant Adenocarcinoma

August 21st 2013

Case Study: Progression on ALK Inhibitors in NSCLC

August 21st 2013

Case Study: MET and ALK Targeted Therapies in NSCLC

August 21st 2013

Case Study: Second-Line Treatment of Adenocarcinoma

August 21st 2013

PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

August 21st 2013

Case Study: Mutation-Negative Patient With Adenocarcinoma

August 21st 2013

Case Study: Maintenance Therapy in Squamous NSCLC

August 21st 2013

Case Study: Treating an Elderly Patient With Squamous NSCLC

August 21st 2013

x